Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say

Investing.com Gold reports: Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say. Full body text was unavailable at ingest time, so this brief is based on headline context.